Pure Global
NCT06381440

Traditional Versus Progressive Robot-assisted Gait Training in People With Multiple Sclerosis and Severe Gait Disability

Traditional Versus Progressive Robot-assisted Gait Training in People With Multiple Sclerosis and Severe Gait Disability: Study Protocol for a the PROGR-EX Randomized-controlled Trial
University Hospital of Ferrara·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Sclerosis
Drug/Device/Intervention
Lokomat device (Hocoma AG, Volketswil, Switzerland).
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
University Hospital of Ferrara
Location
Ferrara, Italy
Timeline & enrollment
Phase
N/A
Start date
Nov 15, 2023
End date
Nov 30, 2024
Enrollment
24 participants
Primary outcome

Walking function

Summary

Multiple sclerosis (MS) is a demyelinating neurodegenerative disease. Qualitative alterations
 in walking function in MS people involve 75% of subjects with MS and are determined by
 reduced coordination, mobility, balance, and increased risk of falling. Robot assisted gait
 training (RAGT) devices seem effective in MS patients with severe motor disabilities, failing
 to show significant superiority when compared to intensive overground gait rehabilitation
 (OGT). This study aims to evaluate the effects of a low-intensity RAGT at progressively
 increasing intensity compared to conventional RAGT and OGT.

ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06381440
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06381440 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital of Ferrara and is currently Recruiting. The study focuses on Multiple Sclerosis. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.